BAVARIAN NORDIC/S (BVNRY) versus DBV Technologies (DBVT) Head to Head Analysis
DBV Technologies (NASDAQ: DBVT) and BAVARIAN NORDIC/S (OTCMKTS:BVNRY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.
This table compares DBV Technologies and BAVARIAN NORDIC/S’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations for DBV Technologies and BAVARIAN NORDIC/S, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
DBV Technologies currently has a consensus target price of $48.86, indicating a potential upside of 129.92%. Given DBV Technologies’ stronger consensus rating and higher possible upside, analysts plainly believe DBV Technologies is more favorable than BAVARIAN NORDIC/S.
Institutional & Insider Ownership
45.1% of DBV Technologies shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares DBV Technologies and BAVARIAN NORDIC/S’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|DBV Technologies||$13.45 million||90.12||-$166.93 million||($3.37)||-6.31|
|BAVARIAN NORDIC/S||$208.06 million||4.90||$27.54 million||$0.29||36.59|
BAVARIAN NORDIC/S has higher revenue and earnings than DBV Technologies. DBV Technologies is trading at a lower price-to-earnings ratio than BAVARIAN NORDIC/S, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
DBV Technologies has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, BAVARIAN NORDIC/S has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500.
DBV Technologies beats BAVARIAN NORDIC/S on 9 of the 13 factors compared between the two stocks.
DBV Technologies Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
BAVARIAN NORDIC/S Company Profile
Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of novel vaccines for the prevention and treatment of life-threatening infectious diseases and cancer. The company markets non-replicating smallpox vaccine under the IMVAMUN and IMVANE names. It is also developing MVA-BN Filo that is in Phase III trial for the treatment of Ebola and Marburg; MVA-BN RSV, which is in Phase II clinical development stage for the prevention of respiratory syncytial virus; and MVA-BN HPV that is in preclinical development stage to treat human papillomavirus. In addition, the company is developing PROSTVAC, which is in Phase III clinical development for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer; CV301 that is in Phase II clinical trial for the treatment multiple cancers; and MVA-BN Brachyury that has completed Phase I clinical trial for the treatment of metastatic cancer. The company has collaboration agreements with National Cancer Institute; Bristol-Myers Squibb; Janssen Pharmaceuticals, Inc.; and Biomedical Advanced Research and Development Authority. It also has a license and collaboration agreement with Janssen Pharmaceuticals, Inc. to leverage its MVA-BN technology with Janssen's AdVac and DNA-based vaccine technologies for the development and commercialization of new vaccine regimens against hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1); and collaboration agreement with US Department of Defense for the development of a prophylactic vaccine against the equine encephalitis virus. The company operates in the United States, Holland, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is headquartered in Kvistgaard, Denmark.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.